Target intelligence / Profile preview

Ribosomal protein L23a pseudogene 64 (RPL23AP64)

Target: RPL23AP64
Molecular classification: Other (Pseudogene)

Overview

RPL23AP64 (ribosomal protein L23a pseudogene 64) is a processed pseudogene in the human genome. It is a non-protein-coding sequence derived from the ribosomal protein L23a gene but does not produce a functional protein. Like most pseudogenes, it may serve as a transcript with possible regulatory impact, though no direct functional or disease association has been found. It is not considered a drug target, receptor, enzyme, or protein of therapeutic interest.

Other names: RPL23A_25_1182GC11M118379GC11M118873GC11M114813other obsolete GeneCards IDs

Mechanism of action

None

Biological functions

None (no confirmed direct role); potential non-coding RNA regulatory functions possible

Disease associations

None established

Beyond the preview

Go deeper on Ribosomal protein L23a pseudogene 64 (RPL23AP64).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribosomal protein L23a pseudogene 64 (RPL23AP64).

Explore the full profile